Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae

Infection and Immunity

Volumn 69, Issue 10, 2001, Pages 6434-6444

  Goetsch, L ^a   Gonzalez, A ^a   Plotnicky Gilquin, H ^a   Haeuw, J F ^a   Aubry, J P ^a   Beck, A ^a   Bonnefoy, J Y ^a   Corvaia N ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL PROTEIN; CARRIER PROTEIN; GLYCOPROTEIN P 15095; PROTEIN A; PROTEIN G; PROTEIN P40; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; FEMALE; IMMUNIZATION; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LYMPHOID TISSUE; MACROPHAGE; MOUSE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; BIOLOGICAL TRANSPORT; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, MUCOSAL; KLEBSIELLA PNEUMONIAE; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NASAL MUCOSA; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINATION; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 0034818555     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.10.6434-6444.2001     Document Type: Article

References (41)

1. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen
2. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
3. Diversity of antibody-mediated immunity at the mucosal barrier
4. Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice
5. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactived measles virus administered intranasally to mice
6. Effect of priming with carrier on response to conjugate vaccine
7. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems
8. The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides
9. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant
10. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
11. Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen
12. Carrier-priming leads to hapten-specific suppression
13. Epitope-specific regulation. Carrier-specific induction of suppression for IgG anti-hapten antibody responses
14. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant
15. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant
16. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway
17. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: An overview
18. Nasal vaccine from fundamental concepts to vaccine development
19. Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier
20. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG
21. Rapid dendritic cell recruitement is a hallmark of the acute inflammatory response at mucosal surfaces
22. A filter immunoplaque assay for the detection of antibody-secreting cells in vitro
23. Epithelial M cells: Gateways for mucosal infection and immunization
24. Chromosomal sequencing using PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A of Klebsiella pneumoniae
25. Induction of local and systemic immunity against human respiratory, syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit
26. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein
27. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae
28. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans
29. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit
30. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain
31. Carrier-induced suppression of antibody response to a self hapten
32. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice
33. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines
34. Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine
35. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
36. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
37. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization virus surface antigen
38. New strategies for using mucosal vaccination to achieve more effective immunization
39. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice
40. Humoral mucosal and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine
41. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of effects of preexisting anti-CT immunity